3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
60
Breast Neoplasms
21
Neoplasms
19
Fallopian Tube Neoplasms
16
Prostatic Neoplasms
15
Neoplasm Metastasis
9
Pancreatic Neoplasms
8
Endometrial Neoplasms
8
Glioblastoma
7
Triple Negative Breast Neoplasms
6
Lung Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Small Cell Lung Carcinoma
4
Glioma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Mesothelioma
3
Melanoma
3
Head and Neck Neoplasms
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Solid Tumor
2
Sarcoma
2
Prostatic Neoplasms, Castration-Resistant
2
Ovarian Diseases
2
Mesothelioma, Malignant
2
Interventions
Temozolomide
73
Radiotherapy
33
Carboplatin
21
Bevacizumab
18
Irinotecan
16
Carmustine
16
Magnetic Resonance Spectroscopy
15
Vincristine
14
Surgical Procedures, Operative
13
Filgrastim
13
Procarbazine
10
Erlotinib Hydrochloride
8
Cyclophosphamide
8
Peripheral Blood Stem Cell Transplantation
7
O(6)-benzylguanine
7
Lomustine
7
Etoposide
7
sargramostim
6
Imatinib Mesylate
6
Flucytosine
6
Cisplatin
6
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
6
temsirolimus
5
Vorinostat
5
Thiotepa
5
Radiotherapy, Intensity-Modulated
5
Radiation
5
Biopsy
5
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
5
vocimagene amiretrorepvec
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Oligodendroglioma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts